Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

1 Jun 2010

Abstract excerpt

BACKGROUND: Various biomarkers for prediction of distant metastasis in lymph-node negative breast cancer have been described; however, predictive biomarkers for patients with lymph-node positive (LNP) disease in the context of distinct systemic therapies are still very much needed. DNA methylation is aberrant in breast cancer and is likely to play a major role in disease progression. In this study, the DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Risks and Factors
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20515469
DOI: 10.1186/1471-2407-10-247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer PatientsPMID 20515469Read ↗

A seven-gene CpG-island methylation panel predicts breast cancer progressionSemantic proximity Read ↗

Promoter Methylation of <i>CDO1</i> Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival OutcomeSemantic proximity Read ↗

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patientsSemantic proximity Read ↗

Prognostic and immune correlation of IDO1 promoter methylation in breast cancerSemantic proximity Read ↗

Identification of differentially methylated genes as diagnostic and prognostic biomarkers of breast cancerSemantic proximity Read ↗

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cellsSemantic proximity Read ↗

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment responseSemantic proximity Read ↗

Genome-wide DNA methylation analysis reveals estrogen-mediated epigenetic repression of metallothionein-1 gene cluster in breast cancerSemantic proximity Read ↗

Genetic variants in oxidative stress-related genes predict chemoresistance in primary breast cancer: a prospective observational study and validation.Semantic proximity Read ↗

Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer.Semantic proximity Read ↗

The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.Semantic proximity Read ↗

MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.